69results about How to "Suppress symptoms" patented technology

The present invention teaches a method and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, metabolic disease, and other conditions. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism. The apparatus and methods include a conformal neuromodulator array which facilitates minimally invasive placement of neuromodulators in communication with target tissues.

The present invention teaches methods and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism.

The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.

The invention provides non-immunostimulatory polynucleotide antigen conjugates and methods for treating unwanted immune reactions in individuals using the non-immunostimulatory polynucleotide antigen conjugates.

The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low Koff rate. In preferred embodiments, agents of the invention are monoclonal antibodies. The invention also provides pharmaceutical compositions comprising one or more EphA2 agonistic agents of the invention either alone or in combination with one or more other agents useful in therapy for non-neoplastic hyperproliferative cell or excessive cell accumulation disorders.

A food composition for preventing type I allergy, a pharmaceutical composition for preventing or treating type I allergy and an external preparation for skin for preventing or treating type I allergy.

The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.

A hand-held aerosolized inhaler that delivers an aerosolized solution to the user on demand when he or she inhales is provided. A pressure or flow sensor within the invention detects the change in air flow as the user inhales and triggers spraying the aerosol solution only when the inhaled breath stream will optimally entrain the sprayed aerosol. The pressure or flow sensor sends an electronic signal to turn on or off liquid and air pumps as the user breathes. Liquid, or liquid and air are pumped to the nozzle inside the invention to create an aerosolized mixture.

The present invention discloses one kind of medicine for treating rhinitis, and the medicine is prepared with centipeda herb 100-500 weight portions, rhubarb 50-300 weight portions, lily magnolia 50-300 weight portions, cocklebur fruit 50-300 weight portions, mint 50-300 weight portions and borneol 1-10 weight portions. The medicine has obvious systemic and local antiallergic effect and antiphlogistic effect, and is used in treating allergic rhinitis, chronic rhinitis, etc. It has fast acting, determined curative effect, high safety and less toxic side effect. The present invention also discloses the preparation process of the medicine.

The present invention relates to plants with enhanced tolerance to viral diseases, particularly to diseases caused by insect-transmitted viruses. The invention discloses transgenic plants expressing GroEL protein, and to engrafted plant comprising said transgenic plants or parts thereof, that are tolerant to insect-transmitted viral diseases. The present invention further discloses means and methods of producing same.

The purpose of the present invention is to provide a dialysis agent A, which is able to set the total acetate ion content in the dialysate to a low value, excellent in storage stability of glucose, able to reduce the acetic acid odor, and able to suppress the corrosion of the dialysate delivery system and the dialysis machine, as well as to provide a two pack type dialysis agent utilizing the dialysis agent A.

In the dialysis agent A used in the preparation of a bicarbonate dialysate, which is used as one part of a two pack type dialysis agent, it becomes possible to prepare a bicarbonate dialysate having the total acetate ion concentration of between 2 mEq/L or more and less than 6 mEq/L by allowing to include glucose, acetic acid and acetate salt and to satisfy the molar ratio of 1:0.5 to 2 of acetic acid and acetate salt, and include acetic acid and acetate salt in a total amount of between 2 mEq or more and less than 6 mEq in the dialysis agent A required to prepare 1 L of the bicarbonate dialysate. Moreover, according to the dialysis agent A, in addition to the excellent stability of glucose, it is possible to reduce the acetic acid odor, and furthermore possible to suppress the corrosion of the dialysate delivery system and the dialysis machine.

The present disclosure provides a method for alleviating or suppressing tobacco or nicotine associated withdrawal symptoms and ease smoking cessation in individuals who wish to quit or decrease smoking tobacco or nicotine comprising the use of probiotic microorganisms.

The invention discloses application of extracellular vesicles in preparation of a preparation for treating or preventing metabolic inflammatory syndrome diseases. The metabolic inflammatory syndrome diseases comprise one or more of obesity, atherosclerosis and diabetes mellitus. The invention discloses a plurality of applications of induced extracellular vesicles from the aspects of appearance and mechanism. The invention also discloses application of an apoptosis vesicle detection reagent in preparation of an obesity detection reagent or kit.

The present invention belongs to pharmaceutical field, specifically, relates to use of Edaravone in the preparation of a medicament for preventing and treating cerebral amyloid angiopathy (CAA). By administering Edaravone, the present invention could scavenge the deposited amyloid (Aβ) in the brain and prevent the intracerebral Aβ deposition.

The invention relates to a traditional Chinese medicine composition for treating ankylosing spondylitis. The traditional Chinese medicine composition comprises the following main components: oldenlandia diffusa, monkshood, radix angelicae tuhuo, cowherb seed, herba epimedii, radix achyranthis bidentatae, rhizoma cibotii, poria cocos, lycopodium clavatum, cistanche, pyrola, ligusticum wallichii and antler. The traditional Chinese medicine composition for treating ankylosing spondylitis, which is provided by the invention, can be used for effectively inhibiting a symptom of ankylosing spondylitis and is remarkable in treatment effect.